ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
Rhea-AI Summary
ADC Therapeutics (NYSE:ADCT) announced a strategic reorganization focused on advancing the ZYNLONTA franchise, including LOTIS-5 and LOTIS-7 trials. The plan includes an estimated 17% workforce reduction, expected annualized savings of about $10 million, one-time charges of roughly $3 million, and an expected cash runway into 2028.
Positive
- Planned ~17% workforce reduction expected to generate about $10 million in annualized cost savings
- One-time pre-tax reorganization charges estimated at only $3 million, mostly in Q2 2026
- Company expects cash runway to extend at least into 2028
- Resources refocused on ZYNLONTA regulatory milestones, including planned LOTIS-5 sBLA submission in Q4 2026
- Ongoing LOTIS-7 Phase 1b trial data anticipated by end of 2026
Negative
- Global workforce to be reduced by approximately 17%
- Company expects about $3 million in one-time pre-tax severance and related termination costs
News Market Reaction – ADCT
On the day this news was published, ADCT declined 6.96%, reflecting a notable negative market reaction. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $136.73M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 03 | Phase 3 results | Positive | -57.1% | LOTIS-5 Phase 3 topline met primary endpoint with improved PFS and responses. |
| May 04 | Quarterly earnings | Neutral | -3.9% | Q1 2026 results with higher ZYNLONTA sales but ongoing net loss and cash burn. |
| May 01 | Inducement grants | Neutral | +1.3% | Equity option grants to new employees under inducement plan for hiring incentives. |
| Apr 27 | Conference call notice | Neutral | -4.6% | Announcement of upcoming Q1 2026 results conference call and webcast logistics. |
| Apr 01 | Inducement grant | Neutral | -0.5% | Single inducement option grant to a new employee with standard four-year vesting. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows frequent negative or muted price reactions even to clinically or operationally positive updates.
Key Terms
pre-supplemental biologics license application regulatory
antibody drug conjugates medical
diffuse large b-cell lymphoma medical
investigator-initiated trials medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Planned ~
Company focused on delivering upcoming regulatory and clinical milestones, including planned
LAUSANNE,
As part of the reorganization, ADC Therapeutics plans to reduce its workforce globally by approximately 17 percent. The reduction is driven by the expected completion of the
"As we further assess the Phase
The Company is preparing for a scheduled pre-sBLA meeting with the FDA in August 2026 to discuss the potential regulatory path forward for ZYNLONTA in combination with rituximab to treat relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) following the recent topline data results from the Phase
In addition, the Company continues to advance the ZYNLONTA franchise through the ongoing Phase
ADC Therapeutics expects the reorganization to generate annualized estimated cost savings of approximately
About ZYNLONTA®
ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.
The
ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).
ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.
Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the cost and effects of the strategic restructuring and workforce reduction including our ability to achieve the estimated cost savings; the adequacy of the LOTIS-5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign jurisdictions for our product; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA; the timing, submission and acceptance of an sBLA submission related to LOTIS-5 and potential approval; the actual and perceived benefit-risk profile for ZYNLONTA as studied in the LOTIS-5 trial; the assessment of the data from LOTIS-5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub-populations; the path for full regulatory approval for ZYNLONTA in the United States and foreign jurisdictions; our ability to identify and execute value-maximizing options and the cost and impact of such options; our expected cash runway into at least 2028 assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; our ability to comply with the terms of our indebtedness; changes in our regulatory and commercial strategy; the Company's ability to sustain or grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing, results and publication of the Company's clinical trials including LOTIS-7; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.
CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-announces-strategic-reorganization-to-support-zynlonta-growth-opportunities-and-regulatory-priorities-302808358.html
SOURCE ADC Therapeutics SA